Trial Profile
3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Anatabine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms ASAP
- Sponsors Rock Creek Pharmaceuticals
- 29 Apr 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 05 Mar 2014 Status has changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 14 May 2013 Planned end date changed from 1 Nov 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.